Evidence map›Paper›PMID 40396196›Full record

ArticleBiology open2025

A novel 14-3-3θ phosphomimetic mouse model demonstrates social dominance defects.

Mary A Gannon, Thanushri Srikantha, Rudradip Pattanayak, Navya Kapa, Aneesh Pathak, A Claire Roberts, William J Stone, Kasandra Scholz, Roschongporn Ekkatine, Talene A Yacoubian

Abstract read
In one paragraph

Article in Biology open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mary A GannonUniversity of Alabama at Birmingham, Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, Birmingham, AL 35294, USA.ORCID 0000-0001-9591-9711
Thanushri SrikanthaUniversity of Alabama at Birmingham, Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, Birmingham, AL 35294, USA.
Rudradip PattanayakUniversity of Alabama at Birmingham, Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, Birmingham, AL 35294, USA.
Navya KapaUniversity of Alabama at Birmingham, Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, Birmingham, AL 35294, USA.
Aneesh PathakUniversity of Alabama at Birmingham, Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, Birmingham, AL 35294, USA.
A Claire RobertsUniversity of Alabama at Birmingham, Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, Birmingham, AL 35294, USA.
William J StoneUniversity of Alabama at Birmingham, Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, Birmingham, AL 35294, USA.
Kasandra ScholzUniversity of Alabama at Birmingham, Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, Birmingham, AL 35294, USA.
Roschongporn EkkatineUniversity of Alabama at Birmingham, Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, Birmingham, AL 35294, USA.
Talene A YacoubianUniversity of Alabama at Birmingham, Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, Birmingham, AL 35294, USA.ORCID 0000-0003-2227-7310

Funding

UAB Alzheimer's Disease Research CenterP30AG086401 · NIA · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Erik D Roberson · 2024 to 2026
$17.1M
14-3-3 phosphorylation in Parkinson's diseaseR01NS112203 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI YACOUBIAN, TALENE ALENE · 2019 to 2023
$2.3M
NIA NIH HHS P30 AG086401NIH HHS R01NS112203NINDS NIH HHS R01 NS112203NINDS NIH HHS R01NS112203Parkinson Association of AlabamaUniversity of Alabama at Birmingham
6 · The paper itself

Abstract

14-3-3 proteins, particularly the 14-3-3θ isoform, are neuroprotective in several models of Parkinson's disease (PD). Evidence for increased 14-3-3θ phosphorylation observed in PD and other neurodegenerative diseases points to a possible pathogenic role for 14-3-3θ phosphorylation in neurodegenerative disease. We recently created a novel conditional knock-in mouse to express the 14-3-3θ S232D phosphomimetic mutation. After crossing this conditional knock-in mouse with the Emx1-Cre mouse in order to induce expression of the S232D mutation in the cortex and hippocampus, we evaluated the effect of 14-3-3θ phosphorylation on behavior and pathology. These mice demonstrated mild motor deficits and reduced social dominance behavior but showed normal cognition and anxiety levels compared to Cre control mice. S232D mice did not show any α-synuclein or phospho-tau pathology at baseline, and dendritic arborization was normal in primary hippocampal cultures from S232D mice. Overall, this mouse model is a novel tool that can be used to look at the effect of 14-3-3θ phosphorylation at S232 in the context of neurodegenerative disease models.

Indexed as

14-3-3 ProteinsSocial DominanceAnimalsBehavior, AnimalDisease Models, AnimalHippocampusMiceMice, TransgenicMutationPhosphorylation14-3-3 Proteins14-3-3Alpha-synucleinAlzheimer's diseaseMouse modelsNMDA receptorsParkinson's diseasePhosphorylationTau

Identifiers

PMID40396196
PMCPMC12182864

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.